We aimed to investigate the causal effect of circulating uric acid concentrations on type 2 3 diabetes risk. A Mendelian randomization study was performed using a genetic score with 24 4 uric acid associated loci. We used data of the EPIC-InterAct case-cohort study, comprising 5 24,265 individuals of European ancestry from eight European countries. During a mean (SD) 6 follow-up of 10 (4) years, 10,576 verified incident type 2 diabetes cases were ascertained. 7 Higher uric acid associated with higher diabetes risk following adjustment for confounders, 8 with a HR of 1.20 (95%CI: 1.11,1.30) per 59.48 µmol/L (1 mg/dL) uric acid. The genetic 9 score raised uric acid by 17 µmol/L (95%CI: 15,18) per SD increase, and explained 4% of 10 uric acid variation. Using the genetic score to estimate the unconfounded effect found that a 11 59.48 µmol/L higher uric acid concentration did not have a causal effect on diabetes (HR 12 1.01, 95%CI: 0.87,1.16). Including data from DIAGRAM consortium, increasing our dataset 13 to 41,508 diabetes cases, the summary OR estimate was 0.99 (95%CI: 0.92, 1.06). In 14 conclusion, our study does not support a causal effect of circulating uric acid on diabetes risk.
Introduction
For the observational association of uric acid and incident diabetes, we estimated country 139 specific HRs and pooled them through meta-analysis. We used I 2 to quantify heterogeneity 140 between countries. Interactions with sex, age and BMI were tested within each country by 141 including interaction terms in the multivariable models. Country-specific estimates were 142 pooled as described above. 143 For the instrumental variable estimate of uric acid on diabetes risk, we used the weighted 144 genetic score to estimate the unconfounded effect of a 59.48 µmol/L (1 mg/dL) increase in 145 uric acid on diabetes risk. We applied the two stage control function estimator approach (19) 146 for this instrumental variable estimate. Instrumental variable estimates were adjusted for study 147 center, and in a second model sex and BMI were added. Country-specific estimates were 148 pooled as described above. The analyses were repeated in strata of sex, age, BMI, and 149 duration of follow-up . Furthermore, we generated instrumental variable estimates of uric acid 150 on glycemic traits (non-fasting glucose and HbA1c) as described above. 151 Proportional Hazard assumptions were inspected visually using log-minus-log plots, with no 152 deviations detected.
154
Sensitivity analyses 155 Analyses were repeated after excluding participants with HbA1c >6.5% (N=22,146 for 156 observational analysis and 15,380 for instrumental variable analysis). Furthermore, the 157 observational association of uric acid and diabetes was estimated in the population used for 158 the instrumental variable analysis (N=17,118 instead of 24, 265) . Moreover, we re-analysed 159 the instrumental variable estimate of uric acid on diabetes risk using the non-weighted genetic 160 score, excluding SNPs that were not statistically significantly associated with uric acid in our 161 study, excluding proxy SNPs with r 2 < 0.80, and excluding SNPs (rs734553; rs2231142) with 162 the strongest effects on uric acid (Online supplementary table 1 ).
Power 164
We estimated the power for the Mendelian randomization analysis at a 2-sided alpha of 0.05 165 based on the sample size and proportion of cases, strength of the genetic instrument, and the 166 expected causal hazards ratio using the online tool mRnd 167 (http://glimmer.rstudio.com/kn3in/mRnd/) (20) . In order to maximize power, we additionally incorporated data made publicly available by 171 GWAS consortia. For fasting glucose (n=58,074) and HOMA-IR (n=37,073), we used data 172 from the MAGIC consortium, which is a collaborative effort that combined data from 173 multiple GWAS to identify genetic determinants that impact on glycemic and metabolic traits.
174
Participants were of European ancestry, and genotyped with the Metabochip (21 In the observational analysis, uric acid was associated with higher diabetes risk, with a HR of 
216
Although all country specific HRs directed towards a higher diabetes risk with higher uric 217 acid concentrations, there was substantial heterogeneity between countries (I 2 70%, P-value 226 Individual uric acid associated SNPs were all directly associated with uric acid, with the 227 strongest association for rs734553 on locus SLC2A9 ( Table 3 ). The individual SNPs were 228 generally not associated with diabetes risk (Table 3) . 229 The mean (SD) uric acid associated genetic score was 1.55 (0.25) in both the subcohort and 230 diabetes cases, and normally distributed among the study participants. A one SD higher Association of genetic score with potential confounders or mediators 238 The uric acid associated genetic score was associated with higher triglyceride concentrations The results of the observational analysis are in line with previous reports(1;2). Two previous 280 meta-analyses showed 6-17% higher diabetes risk per 59.48 µmol/L (1 mg/dL) uric acid. We 281 found a 20% higher risk per 59.48 µmol/L (1 mg/dL) which is comparable to the previous 282 studies. However, residual confounding and/or reverse causality may explain these 283 associations, since we did not find evidence for such an association in instrumental variable (28), and triglycerides (29) . For blood pressure, the results are mixed, with reports of 294 no effect (26) , reducing effects(30;31), and increasing effects(32) (Online supplementary 295 Table 8 ). 296 There are observations that support a potential causal role of uric acid, whereas others suggest Mendelian randomization studies (36) , and the corresponding F-statistic was high, indicating 319 we are unlikely to suffer from weak instrument bias (13) . Second, our study investigated the 320 effect of circulating uric acid in blood, and does not necessarily also reflect effects of 321 intracellular uric acid. Individual SNPs in the gene score may have differential effects on uric 322 acid concentration by body compartment (34;37) . Despite this, it is not plausible there will be 323 common pleiotropy among the individual SNPs included in the score, and any pleiotropic 324 roles of SNPs should be balanced out by use of a polygenic score (38) . Third, our study 325 population was of European ancestry, which limits generalizability to populations of other 326 ancestries.
Associations of individual SNPs and genetic score with uric acid and diabetes

327
Mendelian randomization studies are a valid way to explore evidence for causality, given that 328 certain assumptions are met. First, there has to be a strong association between the instrumental variable and risk factor of interest. All SNPs used in this study have previously 330 been shown to be strongly associated with uric acid concentrations in large meta-analyses of 331 genome wide association studies (9) (10) (11) . Nevertheless, some SNPs did not associate with uric 332 acid in our study. However, when we excluded those SNPs from the genetic score, the null-333 association remained present. Moreover, we strengthened our instrumental variable by using a 334 genetic score of multiple uric acid associated SNPs. No SNPs were in linkage disequilibrium 335 with each other, which justifies combining those SNPs. 336 Second, the instrumental variable must be independent of potential confounders (confounders 337 in the association between uric acid and diabetes). To test this, we examined the associations 338 of the genetic score with potential confounders, and found an association with triglycerides.
339
However, it can be debated whether this is a true confounder, or downstream consequence of 340 uric acid pathways. Moreover, since we did not find an association of uric acid and diabetes in 341 instrumental variable analysis, it is not likely that this is explained by the higher risk of 342 hypertriglyceridemia in individuals with a high genetic score. Indeed, when we additionally 343 adjusted the instrumental variable estimate of uric acid on diabetes risk for triglycerides, the 344 null-effect remained. The observed higher triglyceride concentrations suggests that, although 345 uric acid may not be causally involved in development of diabetes, there may be a separate 346 causal role for uric acid in this metabolic disorder.
347
Third, the instrumental variable affects the outcome only through the risk factor of interest.
348
This assumption is untestable, and should be considered using information on the underlying 349 biology. None of the SNPs used in this study were in linkage disequilibrium with loci known 350 to influence diabetes risk (22;39;40) , which strengthens this assumption. Moreover, the vast 351 majority of SNPs identified in the meta-analysis of Kolz et al. (9) were involved in regulating 352 urate transport across cell membranes, which suggests that these SNPs directly influence uric 353 acid levels. However, SLC2A9, the strongest uric acid associated locus, does not only transport uric acid, but also glucose and fructose (41) , and exchanges uric acid for glucose (42) , 355 leaving room for possible pleiotropy. Moreover, SLC2A9 has recently been shown to have 356 differential effects on urinary and intestinal secretion of uric acid in mouse, suggesting a rise 357 serum uric acid due to reduced urinary secretion could be counterbalanced by increased 358 intestinal secretion and decreased portal vein levels (34) . Similar contrasting roles have been 359 reported for ABCG2 (37) . A sensitivity analysis excluding the SNPs in these loci did not alter 360 the result (Online supplementary table 6).
361
In conclusion, our study does not support the hypothesis that circulating uric acid has a causal 362 effect on diabetes risk. Our findings therefore suggest that increased uric acid concentrations 363 are a consequence of an adverse metabolic profile, rather than a cause of diabetes, and that 364 uric acid has limited value as therapeutic target in preventing diabetes. 
